Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer-Reference-Cited by-同舟云学术

Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer

Published:2021-03-01 Issue:3 Volume:7 Page:436
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Ramaswamy Anant¹,Ostwal Vikas¹,Sharma Atul²,Bhargava Prabhat¹,Srinivas Sujay¹,Goel Mahesh³,Patkar Shraddha³,Mandavkar Sarika¹,Jadhav Poonam¹,Parulekar Manali¹,Choudhari Amitkumar⁴,Gupta Sudeep¹

Affiliation:

1. Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India

2. Department of Medical Oncology, Dr B.R.A Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

3. Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

4. Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2773377/jamaoncology_ramaswamy_2020_br_200020_1615397450.58172.pdf

Reference12 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Bray;CA Cancer J Clin,2018

2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.;Valle;N Engl J Med,2010

3. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.;Sharma;Eur J Cancer,2019

4. Second-line chemotherapy in advanced biliary cancer: a systematic review.;Lamarca;Ann Oncol,2014

5. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.;Lamarca;JCO,2019

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers;Chinese Medical Journal;2024-09-04

2. Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study;The Oncologist;2024-08-05

3. Nanoliposomal irinotecan in advanced biliary tract cancers;The Lancet Gastroenterology & Hepatology;2024-08

4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer;ESMO Open;2024-08

5. Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF);Liver International;2024-07-05